Company news
Cannabis Bioscience International Holdings, Inc. news in 2024
Cannabis Bioscience International Holdings, Inc.'s news releases, calls and decks from 2024, newest first.
CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing
December 15, 2024
A Letter from the Desk of CBIH
December 8, 2024
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
December 3, 2024
CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing
December 1, 2024
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip
November 24, 2024
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
November 17, 2024
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
November 11, 2024
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
November 3, 2024
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
July 14, 2024
CBIH Charts Path to Future Leadership in Cannabis Medicine
July 7, 2024
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
June 30, 2024
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
June 25, 2024
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
June 16, 2024
CBIH and Vita Biotech Forge Alliance to Propel Clinical Studies Forward
June 4, 2024
CBIH Engages Prestigious Law Firm for its First Patent Applications
May 19, 2024
CBIH Welcomes New Treasurer and Director, Mr. John E. Jones
May 5, 2024
CBIH Commences Clinical Trials of Osteoarthritis Injection "Orthocann"
March 19, 2024
CBIH Announces the Retirement of One Billion Shares
March 5, 2024
Brian Cuban Joins Cannabis Bioscience International Holdings as an Advisory Board Member
February 25, 2024
Cannabis Bioscience International Holdings, Inc. Announces Engagement of Bull in Advantage as its Investor Relations Firm
February 19, 2024